Millennium Management LLC trimmed its holdings in Jazz Pharmaceuticals (NASDAQ:JAZZ) by 79.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 27,292 shares of the specialty pharmaceutical company’s stock after selling 103,198 shares during the period. Millennium Management LLC’s holdings in Jazz Pharmaceuticals were worth $3,675,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors have also added to or reduced their stakes in JAZZ. US Bancorp DE lifted its stake in shares of Jazz Pharmaceuticals by 49.5% in the fourth quarter. US Bancorp DE now owns 1,087 shares of the specialty pharmaceutical company’s stock valued at $147,000 after buying an additional 360 shares in the last quarter. Invictus RG bought a new position in shares of Jazz Pharmaceuticals in the fourth quarter valued at $206,000. Ladenburg Thalmann Financial Services Inc. lifted its stake in shares of Jazz Pharmaceuticals by 795.4% in the third quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,746 shares of the specialty pharmaceutical company’s stock valued at $255,000 after buying an additional 1,551 shares in the last quarter. Janney Montgomery Scott LLC lifted its stake in shares of Jazz Pharmaceuticals by 29.4% in the third quarter. Janney Montgomery Scott LLC now owns 1,760 shares of the specialty pharmaceutical company’s stock valued at $257,000 after buying an additional 400 shares in the last quarter. Finally, Robeco Institutional Asset Management B.V. bought a new position in shares of Jazz Pharmaceuticals in the fourth quarter valued at $276,000. 91.21% of the stock is currently owned by hedge funds and other institutional investors.
A number of research firms have weighed in on JAZZ. HC Wainwright reaffirmed a “neutral” rating and issued a $160.00 price objective (up from $150.00) on shares of Jazz Pharmaceuticals in a research note on Friday, March 23rd. Leerink Swann initiated coverage on shares of Jazz Pharmaceuticals in a research report on Tuesday, January 2nd. They set an “outperform” rating and a $180.00 price target on the stock. BidaskClub raised shares of Jazz Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Tuesday, March 13th. B. Riley reissued a “buy” rating and set a $206.00 price target on shares of Jazz Pharmaceuticals in a research report on Tuesday, January 16th. Finally, Deutsche Bank set a $170.00 price target on shares of Jazz Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, January 16th. Six research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $180.78.
Shares of JAZZ stock opened at $157.95 on Friday. The stock has a market capitalization of $9,492.00, a price-to-earnings ratio of 16.52, a P/E/G ratio of 0.83 and a beta of 0.97. The company has a debt-to-equity ratio of 0.57, a quick ratio of 3.15 and a current ratio of 3.29. Jazz Pharmaceuticals has a 52 week low of $128.58 and a 52 week high of $163.75.
Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings data on Tuesday, February 27th. The specialty pharmaceutical company reported $2.58 EPS for the quarter, missing the consensus estimate of $2.73 by ($0.15). The company had revenue of $436.40 million during the quarter, compared to the consensus estimate of $440.91 million. Jazz Pharmaceuticals had a return on equity of 22.63% and a net margin of 30.14%. research analysts predict that Jazz Pharmaceuticals will post 11.48 earnings per share for the current year.
In other news, SVP Paul Treacy sold 877 shares of Jazz Pharmaceuticals stock in a transaction dated Friday, March 2nd. The shares were sold at an average price of $139.62, for a total value of $122,446.74. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Michael Patrick Miller sold 200 shares of Jazz Pharmaceuticals stock in a transaction dated Wednesday, February 14th. The stock was sold at an average price of $139.99, for a total transaction of $27,998.00. Following the completion of the transaction, the executive vice president now owns 21,469 shares of the company’s stock, valued at approximately $3,005,445.31. The disclosure for this sale can be found here. In the last ninety days, insiders sold 14,657 shares of company stock worth $2,189,989. Insiders own 4.30% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Millennium Management LLC Sells 103,198 Shares of Jazz Pharmaceuticals (JAZZ)” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this report on another website, it was copied illegally and republished in violation of international trademark and copyright laws. The legal version of this report can be read at https://www.dispatchtribunal.com/2018/04/22/millennium-management-llc-sells-103198-shares-of-jazz-pharmaceuticals-jazz.html.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.
Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals (NASDAQ:JAZZ).
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.